Lakewood-Amedex Biotherapeutics (LABT) executive compensation, 2026 proxy

Kelvin Cooper, CEO, was paid $563,377 in 2025, down 20% from $705,975 the year before.

Filed
August 10, 2026
Annual meeting
September 22, 2026
Pay year
2025
Named executives
4
CEO total pay
$563,377-20% vs prior year
CFO total compensation
$532,9602025 Summary Compensation Table
CMO total compensation
$488,7172025 Summary Compensation Table
Executive Chair compensation
$48,0002025 Summary Compensation Table
CFO target bonus
35%Of base salary
CMO target bonus
40%Of base salary
CEO option grant
202,703Granted July 2, 2025

How Cooper was paid

$563,377 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary34%Option awards66%

Named executive officers

ExecutiveTotal
Kelvin CooperCEO$563,377
Peter CeccacciCFO$532,960
Thomas BalzerCMO$488,717
Peter B. CorrExecutive Chair$48,000

What changed and why

  • $563K$563,377 CEO total compensation in 2025 decreased from $705,975 in 2024.
  • $373K$372,960 of CEO compensation was stock option grant-date fair value.
  • $190K$190,417 CEO salary in 2025 decreased from $409,167 in 2024.
  • 2025 bonuses were shown as dashes for all named executive officers.
  • 45%45% of base salary was the CEO's targeted annual discretionary bonus.
  • 2025 stock options for Cooper and Ceccacci vested immediately upon grant.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.